MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Annals of the Rheumatic Diseases
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,612 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,612 works in the cohort · of 4,299,418page 21 of 53

Labels cover 7 of 2,612 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,612 of 2,612 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT
Daniel E. Furst, Edward Keystone, Jonathan Kay, Janusz Jaworski, Rafał Wojciechowski, Piotr Wiland +14 more
2021· article· en· Annals of the Rheumatic Diseases· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
2
citations
affaboutno abstractunlabeled
AB0288 Safety, effectiveness, work and household productivity of anti-tnf alpha therapy with certolizumab pegol observed in adult rheumatoid arthritis patients in daily practice in canada: first interim analysis of the non-interventional fast can study
Saeed Ahmed Shaikh, W. Bensen, Andrew Chow, Sanjay Dixit, I. Fortin, Boulos Haraoui +5 more
2013· article· en· Annals of the Rheumatic Diseases· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
← previousnext →

How this was built: Screen · Findings · About